

Double-blind peer review submissions: write DBPR and your manuscript number here

Corresponding author(s): instead of author n

Last updated by author(s): YYYY-MM-DD

# **Reporting Summary**

X Life sciences

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see <u>Authors & Referees</u> and the <u>Editorial Policy Checklist</u>.

Statistics						
For all statistical analyse	es, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.					
n/a Confirmed						
☐ ☐ The exact samp	The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement					
A statement or	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly					
The statistical to	The statistical test(s) used AND whether they are one- or two-sided  Only common tests should be described solely by name; describe more complex techniques in the Methods section.					
A description of	of all covariates tested					
A description of	of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons					
A full description (	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient)  AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)					
For null hypoth	nesis testing, the test statistic (e.g. $F$ , $t$ , $r$ ) with confidence intervals, effect sizes, degrees of freedom and $P$ value noted exact values whenever suitable.					
For Bayesian a	nalysis, information on the choice of priors and Markov chain Monte Carlo settings					
For hierarchica	l and complex designs, identification of the appropriate level for tests and full reporting of outcomes					
Estimates of ef	fect sizes (e.g. Cohen's $d$ , Pearson's $r$ ), indicating how they were calculated					
	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.					
Software and co	ode					
Policy information abou	t <u>availability of computer code</u>					
Data collection  Data collection performed with PatchMaster software (Heka), PhotoTrack system, MicroManager 1.4.13 and a prevoiously pushingle worm tracking software. Custom data collection scripts are available upon request.						
,	Data analysis was standardized as workflows in KNIME 3.5 with statistics calculated in Prism 5.01, Mathematica 10, OriginPro 2015G, ImageJ 1.52i and R 3.3.2 with RStudio 1.0.136. All custom scripts are available upon request.					
	m algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. eposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.					
Data						
- Accession codes, unic - A list of figures that h	t <u>availability of data</u> nclude a <u>data availability statement</u> . This statement should provide the following information, where applicable: que identifiers, or web links for publicly available datasets have associated raw data restrictions on data availability					
All data is available upon r	All data is available upon reasonable request from the authors.					
Field-specif	fic reporting					

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Ecological, evolutionary & environmental sciences

Behavioural & social sciences

# Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size

No statistical methods were applied to predetermine sample size. However, sample sizes reported here are consistent to data presented in previous publications.

Data exclusions

Data exclusion was performed by pre-determined hard coded thresholds in the analysis workflow.

Replication

Measurements were performed on at least three independent animals generations and compared to each other (with no significant changes unless noted). These measurements were then pooled for analysis as a single group.

Randomization

Animals for behavior analysis were randomly selected. For electrophysiological analysis, there is a bias towards larger animals due to the easo of preparation.

Blinding

No blinding was required for behavioral measurements, since analysis was performed by a hard coded workflow. Animals were blinded for electrophysiological analysis.

## Behavioural & social sciences study design

All studies must disclose on these points even when the disclosure is negative.

Study description

Briefly describe the study type including whether data are quantitative, qualitative, or mixed-methods (e.g. qualitative cross-sectional, quantitative experimental, mixed-methods case study).

Research sample

State the research sample (e.g. Harvard university undergraduates, villagers in rural India) and provide relevant demographic information (e.g. age, sex) and indicate whether the sample is representative. Provide a rationale for the study sample chosen. For studies involving existing datasets, please describe the dataset and source.

Sampling strategy

Describe the sampling procedure (e.g. random, snowball, stratified, convenience). Describe the statistical methods that were used to predetermine sample size OR if no sample-size calculation was performed, describe how sample sizes were chosen and provide a rationale for why these sample sizes are sufficient. For qualitative data, please indicate whether data saturation was considered, and what criteria were used to decide that no further sampling was needed.

Data collection

Provide details about the data collection procedure, including the instruments or devices used to record the data (e.g. pen and paper, computer, eye tracker, video or audio equipment) whether anyone was present besides the participant(s) and the researcher, and whether the researcher was blind to experimental condition and/or the study hypothesis during data collection.

Timing

Indicate the start and stop dates of data collection. If there is a gap between collection periods, state the dates for each sample cohort.

Data exclusions

If no data were excluded from the analyses, state so OR if data were excluded, provide the exact number of exclusions and the rationale behind them, indicating whether exclusion criteria were pre-established.

Non-participation

State how many participants dropped out/declined participation and the reason(s) given OR provide response rate OR state that no participants dropped out/declined participation.

Randomization

If participants were not allocated into experimental groups, state so OR describe how participants were allocated to groups, and if allocation was not random, describe how covariates were controlled.

# Ecological, evolutionary & environmental sciences study design

All studies must disclose on these points even when the disclosure is negative.

Study description

Briefly describe the study. For quantitative data include treatment factors and interactions, design structure (e.g. factorial, nested, hierarchical), nature and number of experimental units and replicates.

Research sample

Describe the research sample (e.g. a group of tagged Passer domesticus, all Stenocereus thurberi within Organ Pipe Cactus National Monument), and provide a rationale for the sample choice. When relevant, describe the organism taxa, source, sex, age range and any manipulations. State what population the sample is meant to represent when applicable. For studies involving existing datasets, describe the data and its source.

Sampling strategy

Note the sampling procedure. Describe the statistical methods that were used to predetermine sample size OR if no sample-size calculation was performed, describe how sample sizes were chosen and provide a rationale for why these sample sizes are sufficient.

Data collection

Describe the data collection procedure, including who recorded the data and how.

Timing and spatial scale	dicate the start and stop dates of data collection, noting the frequency and periodicity of sampling and providing a rationale for nese choices. If there is a gap between collection periods, state the dates for each sample cohort. Specify the spatial scale from which he data are taken						
Data exclusions	o data were excluded from the analyses, state so OR if data were excluded, describe the exclusions and the rationale behind them, cating whether exclusion criteria were pre-established.						
Reproducibility	Describe the measures taken to verify the reproducibility of experimental findings. For each experiment, note whether any attempts to repeat the experiment failed OR state that all attempts to repeat the experiment were successful.						
Randomization	Describe how samples/organisms/participants were allocated into groups. If allocation was not random, describe how covariates were controlled. If this is not relevant to your study, explain why.						
Blinding	Describe the extent of blinding used during data acquisition and analysis. If blinding was not possible, describe why OR explain why blinding was not relevant to your study.						
Did the study involve field	l work? Yes No						
Field work, collec	tion and transport						
Field conditions	Describe the study conditions for field work, providing relevant parameters (e.g. temperature, rainfall).						
Location	State the location of the sampling or experiment, providing relevant parameters (e.g. latitude and longitude, elevation, water depth).						
Access and import/expor	Describe the efforts you have made to access habitats and to collect and import/export your samples in a responsible manner and in compliance with local, national and international laws, noting any permits that were obtained (give the name of the issuing authority, the date of issue, and any identifying information).						
Disturbance	Describe any disturbance caused by the study and how it was minimized.						

# Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Ma	terials & experimental systems	Methods			
n/a	Involved in the study	n/a	Involved in the study		
$\boxtimes$	Antibodies	$\boxtimes$	ChIP-seq		
$\boxtimes$	Eukaryotic cell lines	$\boxtimes$	Flow cytometry		
$\boxtimes$	Palaeontology	$\boxtimes$	MRI-based neuroimaging		
	Animals and other organisms		•		
$\boxtimes$	Human research participants				
$\boxtimes$	Clinical data				
	•				

#### **Antibodies**

Antibodies used

Describe all antibodies used in the study; as applicable, provide supplier name, catalog number, clone name, and lot number.

Validation

Describe the validation of each primary antibody for the species and application, noting any validation statements on the manufacturer's website, relevant citations, antibody profiles in online databases, or data provided in the manuscript.

### Eukaryotic cell lines

Policy information about cell lines

Cell line source(s)

State the source of each cell line used.

Authentication

Describe the authentication procedures for each cell line used OR declare that none of the cell lines used were authenticated.

Mycoplasma contamination

Confirm that all cell lines tested negative for mycoplasma contamination OR describe the results of the testing for mycoplasma contamination OR declare that the cell lines were not tested for mycoplasma contamination.

Commonly misidentified lines (See ICLAC register)

Name any commonly misidentified cell lines used in the study and provide a rationale for their use.

#### Palaeontology

Specimen provenance

Provide provenance information for specimens and describe permits that were obtained for the work (including the name of the issuing authority, the date of issue, and any identifying information).

Specimen deposition

Indicate where the specimens have been deposited to permit free access by other researchers.

Dating methods

If new dates are provided, describe how they were obtained (e.g. collection, storage, sample pretreatment and measurement), where they were obtained (i.e. lab name), the calibration program and the protocol for quality assurance OR state that no new dates are provided.

Tick this box to confirm that the raw and calibrated dates are available in the paper or in Supplementary Information.

#### Animals and other organisms

Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research

Laboratory animals

The following strains were used or generated for this study: N2 (wild type isolate, Bristol strain), HBR1777: goels384[pflp-11::egl-1::SL2-mkate2-flp-11-3'utr, unc-119(+)], ZX1466: lite-1(ce314)X;

zx ls 55 [pggr-2::flox::ChR2(H134R)::mCherry::SL2::GFP; pggr-1::Cre], ZX1468: unc-47(e307) III; lite-1(ce314) X; pggr-2::flox::ChR2(H134R)::mCherry::SL2::GFP; pggr-1::Cre], ZX1468: unc-47(e307) III; lite-1(ce314) X; pggr-1::Cre], ZX168: unc-47(e307) III; lite-1(ce314) X; lite-1(ce314) X;

zxls55[pggr-2::flox::ChR2(H134R)::mCherry::SL2::GFP; pggr-1::Cre], ZX1469: unc-31(n1304)IV, lite-1(ce314)X; zxls55[pggr

2::flox::ChR2(H134R)::mCherry::SL2::GFP; pggr-1::Cre], ZX1470: lite-1(ce314)X, zxls55[pggr

2::flox::ChR2(H134R)::mCherry::SL2::GFP; pggr-1::Cre; pmyo-2::mCherry]; zxls52[pmyo-3::RCaMP], ZX1561:

zxIs55[pggr-2::flox::ChR2(H134R)::mCherry::SL2::GFP; pggr-1::Cre], ZX1577: lite-1(ce314)X;

zxEx360[pggr-2::flox::ChR2(H134R)::mCherry::SL2::GFP; pggr-1::Cre], ZX1891: egl 3(gk238)X; lite-1(ce314)X;

 $zxEx360[pggr-2::flox::ChR2(H134R)::mCherry::SL2::GFP; pggr\ 1::Cre], ZX2017: zxls60[pggr-2::flox::GCaMP6s::SL2::tagRFP; pggr\ 1::C$ 

pggr-1::nCre]; zxEx378[pncx-10::mCherry], ZX2099: flp-11(tm2706)X, lite-1(ce314)X, zxEx360[pggr

2::flox::ChR2(H134R)::mCherry::SL2::GFP; pggr 1::Cre], ZX2140: unc-47(e307)III; flp-11(tm2706)X; lite-1(ce314)X; zxEx360[pggr 2::flox::ChR2(H134R)::mCherry::SL2::GFP; pggr 1::Cre], ZX2223: flp-11(tm2706)X, zxEx1173[pggr-2::flox::GCaMP6s::SL2::tagRFP; pggr-1::nCre; pncx 10::mCherry], ZX2297: lite-1(ce314)X, zxEx371[pggr-1::Cre, pggr-2::flox::ChR2(H134R)::mCherry::SL2::GFP, CLAC::iCcaMP1b, pupe 17:OF, pupe 4::OF]

QUAS::jRCaMP1b, punc-17::QF, punc-4::QS].

Wild animals This study did not involve wild animals.

Field-collected samples This study did not involve samples collected from the field.

Ethics oversight Studies on C. elegans do not require ethics oversight.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

#### Human research participants

Policy information about studies involving human research participants

Population characteristics

Describe the covariate-relevant population characteristics of the human research participants (e.g. age, gender, genotypic information, past and current diagnosis and treatment categories). If you filled out the behavioural & social sciences study design questions and have nothing to add here, write "See above."

Recruitment

Describe how participants were recruited. Outline any potential self-selection bias or other biases that may be present and how these are likely to impact results.

Ethics oversight

Identify the organization(s) that approved the study protocol.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

#### Clinical data

Policy information about <u>clinical studies</u>

All manuscripts should comply with the ICMJE guidelines for publication of clinical research and a completed CONSORT checklist must be included with all submissions.

Clinical trial registration Provide the trial registration number from ClinicalTrials.gov or an equivalent agency.

Study protocol Note where the full trial protocol can be accessed OR if not available, explain why.

Data collection Describe the settings and locales of data collection, noting the time periods of recruitment and data collection.

Outcomes Describe how you pre-defined primary and secondary outcome measures and how you assessed these measures.

C	hΙ	P.	-S	e	a

Data	de	$no^{\circ}$	らけ	ınn

Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks.

Data access links

May remain private before publication.

For "Initial submission" or "Revised version" documents, provide reviewer access links. For your "Final submission" document, provide a link to the deposited data.

Files in database submission

Provide a list of all files available in the database submission.

Genome browser session (e.g. <u>UCSC</u>)

Provide a link to an anonymized genome browser session for "Initial submission" and "Revised version" documents only, to enable peer review. Write "no longer applicable" for "Final submission" documents.

#### Methodology

Antibodies

Replicates Describe the experimental replicates, specifying number, type and replicate agreement.

Sequencing depth

Describe the sequencing depth for each experiment, providing the total number of reads, uniquely mapped reads, length of reads and whether they were paired- or single-end.

Describe the antibodies used for the ChIP-seq experiments; as applicable, provide supplier name, catalog number, clone

name, and lot number.

Peak calling parameters Specify the command line program and parameters used for read mapping and peak calling, including the ChIP, control and

illuex files used

Data quality Describe the methods used to ensure data quality in full detail, including how many peaks are at FDR 5% and above 5-fold

enrichment.

Software

Describe the software used to collect and analyze the ChIP-seq data. For custom code that has been deposited into a community repository, provide accession details.

### Flow Cytometry

#### Plots

Confirm that:

The axis	labe	ls state t	he marl	ker and	fluoroc	hrome	used	(e.g.	CD4-FIT	C)	١.

The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).

All plots are contour plots with outliers or pseudocolor plots.

A numerical value for number of cells or percentage (with statistics) is provided.

#### Methodology

Sample preparation Describe the sample preparation, detailing the biological source of the cells and any tissue processing steps used.

**Instrument** Identify the instrument used for data collection, specifying make and model number.

Software

Describe the software used to collect and analyze the flow cytometry data. For custom code that has been deposited into a community repository, provide accession details.

continuinty repository, provide accession details.

and how it was determined.

Gating strategy

Describe the gating strategy used for all relevant experiments, specifying the preliminary FSC/SSC gates of the starting cell population, indicating where boundaries between "positive" and "negative" staining cell populations are defined.

Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.

## Magnetic resonance imaging

#### Experimental design

Design type

Indicate task or resting state; event-related or block design.

Design specifications		Specify the number of blocks, trials or experimental units per session and/or subject, and specify the length of each trial or block (if trials are blocked) and interval between trials.						
Behavioral performance measures		te number and/or type of variables recorded (e.g. correct button press, response time) and what statistics were used establish that the subjects were performing the task as expected (e.g. mean, range, and/or standard deviation across pjects).						
Acquisition								
Imaging type(s)	Specify: fund	ctional, structural, diffusion, perfusion.						
Field strength	Specify in Te	Specify in Tesla						
Sequence & imaging parameters		pecify the pulse sequence type (gradient echo, spin echo, etc.), imaging type (EPI, spiral, etc.), field of view, matrix size, ice thickness, orientation and TE/TR/flip angle.						
Area of acquisition	State wheth	er a whole brain scan was used OR define the area of acquisition, describing how the region was determined.						
Diffusion MRI Used	Not use	ed						
Preprocessing								
Preprocessing software		Provide detail on software version and revision number and on specific parameters (model/functions, brain extraction, segmentation, smoothing kernel size, etc.).						
Normalization	If data were normalized/standardized, describe the approach(es): specify linear or non-linear and define image types used for transformation OR indicate that data were not normalized and explain rationale for lack of normalization.							
Normalization template	Describe the template used for normalization/transformation, specifying subject space or group standardized space (e.g. original Talairach, MNI305, ICBM152) OR indicate that the data were not normalized.							
Noise and artifact removal	Describe your procedure(s) for artifact and structured noise removal, specifying motion parameters, tissue signals and physiological signals (heart rate, respiration).							
Volume censoring	Define your software and/or method and criteria for volume censoring, and state the extent of such censoring.							
Statistical modeling & inference	9							
Model type and settings		(mass univariate, multivariate, RSA, predictive, etc.) and describe essential details of the model at the first levels (e.g. fixed, random or mixed effects; drift or auto-correlation).						
Effect(s) tested		se effect in terms of the task or stimulus conditions instead of psychological concepts and indicate whether actorial designs were used.						
Specify type of analysis: Whole	e brain	ROI-based Both						
Statistic type for inference (See <u>Eklund et al. 2016</u> )	Specify voxe	l-wise or cluster-wise and report all relevant parameters for cluster-wise methods.						
Correction	Describe the type of correction and how it is obtained for multiple comparisons (e.g. FWE, FDR, permutation or Monte Carlo).							
Models & analysis								
n/a   Involved in the study								
Functional and/or effective cor	nectivity							
Graph analysis								
Multivariate modeling or predi	ctive analysis							
Functional and/or effective connect	vity	Report the measures of dependence used and the model details (e.g. Pearson correlation, partial correlation, mutual information).						
Graph analysis		Report the dependent variable and connectivity measure, specifying weighted graph or binarized graph, subject- or group-level, and the global and/or node summaries used (e.g. clustering coefficient, efficiency, etc.).						

Multivariate modeling and predictive analysis

Specify independent variables, features extraction and dimension reduction, model, training and evaluation metrics.